Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Immunocore Signs Research and Licensing Agreement with GlaxoSmithKline

Published: Tuesday, July 09, 2013
Last Updated: Tuesday, July 09, 2013
Bookmark and Share
Companies collaborate to discover ImmTACs against novel targets.

Immunocore Limited announced it has entered into a partnership with GlaxoSmithKline (GSK) for multiple novel targets not addressable using antibody-based technologies. This is Immunocore’s second major partnership this year.

Under the terms of the agreement, Immunocore will receive up to a total of £142 million in pre-clinical milestone payments across the targets. In addition, for each product that reaches the market, up to £200 million is due to Immunocore in development and commercial milestone payments, plus up to double digit royalties.

Immunocore will be responsible for all of the pre-clinical development and for the initial clinical trials in patients and GSK will be responsible for the remaining development and commercialisation of the products.

Immunocore has created a world-leading platform of bi-specific biological drugs, called ImmTACs (Immune mobilising mTCR Against Cancer), which exploit the power of T Cell Receptors (TCRs) to recognise intracellular changes that occur during cancer or viral infection. This unique recognition ability of TCRs sets them apart from traditional antibody-based therapies that can only recognise changes on the surface of cells, and provides, for the first time, the ability to develop extremely potent targeted therapies for cancers that are currently poorly served.

The most advanced ImmTAC drug, IMCgp100 for the treatment of melanoma, is currently in Phase I/II clinical trials in the UK and USA.

James Noble, Chief Executive Officer of Immunocore, commented: “We are delighted to collaborate with GSK, our second major partnership signed this year. GSK is a leading pharmaceutical company with a proven track record in the development of biotherapeutics and this is an important partnership for Immunocore.”

Laurent Jespers, VP and Head of Innovation BDU, Biopharm R&D of GSK, said: “We are very excited about the opportunity to work together with Immunocore to develop ImmTACs. We believe ImmTACs offer a tremendous opportunity in treating cancer and in other areas where there is a large unmet medical need.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immunocore Appoints Dr Eliot Forster as Chief Executive Officer
Immunocore Limited has announced the appointment of Dr Eliot Forster as Chief Executive Officer with immediate effect.
Monday, January 12, 2015
Immunocore and MedImmune Win the SCRIP Award
Immunocore and MedImmune are working together to generate ImmTACs against selected cancer targets.
Thursday, December 11, 2014
Immunocore and Lilly Enter Immunotherapy Agreement
Agreement to co-discover and co-develop novel cancer therapies.
Thursday, July 17, 2014
Immunocore to Present at 32nd Annual JP Morgan Healthcare Conference
Company to provide an update on lead programme for melanoma.
Thursday, January 16, 2014
Immunocore and MedImmune Enter Immunotherapy Agreement
Companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer technology.
Wednesday, January 08, 2014
Immunocore Appoints New Chairman of the Board
Dr Jonathan Knowles appointed as Company’s new executive Chairman of the Board of Directors.
Monday, November 18, 2013
Immunocore Appoints Chairman
Immunocore Limited announced the appointment of Dr Jonathan Knowles as the new executive Chairman of the Board of Directors with immediate effect.
Thursday, November 14, 2013
Immunocore Achieves Research Milestone in GSK Collaboration
Under the agreement announced in July, Immunocore will receive up to £142 million in pre-clinical milestone payments across the targets.
Thursday, November 07, 2013
Immunocore Named One of Fierce 15 Leading Biotechs of 2013
Immunocore ranked among the top private biotech firms globally.
Thursday, September 26, 2013
Immunocore Announces Appointment of Eva-Lotta Allan to the Board
New position will strengthen management team as company expands operations.
Thursday, May 02, 2013
Revolutionary New Cancer Targeting Technology Described in Nature Medicine
Immunocore scientists manage to overcome cancer problem by boosting the ability of cancer-specific TCRs.
Monday, May 07, 2012
Clinical Trials of New Treatment for Advanced Melanoma In UK and USA
Researchers at Immunocore Limited have announced that IMCgp100, a targeted therapeutic for the treatment of advanced metastatic melanoma, has received regulatory and ethics approval and has opened enrolment for clinical trials in the UK and USA.
Thursday, November 04, 2010
Clinical Trials of New Treatment for Advanced Melanoma in UK and USA
Researchers at Immunocore Limited have announced that IMCgp100, a targeted therapeutic for the treatment of advanced metastatic melanoma, has received regulatory and ethics approval and has opened enrolment for clinical trials in the UK and USA.
Thursday, October 28, 2010
Scientific News
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos